生物制药
生化工程
免疫原性
计算生物学
残余物
制造工艺
计算机科学
重组DNA
风险分析(工程)
药物开发
过程开发
药品
生物技术
化学
工艺工程
医学
药理学
材料科学
生物
免疫系统
生物化学
工程类
基因
免疫学
算法
复合材料
作者
Yifan Yao,Xuemei Wen,Hongjuan Pan,Ziwei Chen
标识
DOI:10.3389/fmicb.2025.1658366
摘要
Host cell proteins (HCPs) are process-related impurities derived from host organisms used for recombinant protein production in biopharmaceutical manufacturing. The generation of HCPs may lead to potential safety risks, such as immunogenicity, reduced drug efficacy and long-term side effects. Therefore, in the biopharmaceutical process, even trace amounts of HCPs need to be strictly regulated and controlled. The main bottlenecks associated with the detection of HCPs include a wide dynamic range of detection and instability of HCPs. Due to its high sensitivity and high resolution, mass spectrometry has attracted more and more attention in HCP detection, but it still cannot completely replace enzyme-linked immunosorbent assay (ELISA). The research in the future includes the development of more efficient sample pretreatment methods and data processing techniques to improve the sensitivity and accuracy of detection. At the same time, combined with risk assessment and process optimization, it is expected to further reduce the residual risk of HCP. This review discusses the sources, properties, pretreatment and detection of residual HCPs in therapeutic products, along with current regulatory considerations and future advancements.
科研通智能强力驱动
Strongly Powered by AbleSci AI